New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
Case Study: Reptor Phage Enrichment
Project Summary Phage display is a powerful toolkit for antibody discovery and engineering. In this study, we used phage display to identify Cas9-binding single domain (VHH) antibodies. In addition to traditional colony picking, we used our Reptor immune repertoire...
Abterra Bio Has Moved To Sorrento Valley
Abterra Bio Has Moved To Sorrento Valley In 2009, Abterra Bio began as Digital Proteomics LLC, a spin-out of the University of California – San Diego. Founders Pavel Pevzner and Vineet Bafna, as well as Natalie Castellana, Stefano Bonissone, and Anand Patel have been...
Advantages of High-Throughput Hybridoma Sequencing with NGS
Having a diverse collection of leads at the beginning of your antibody development campaign is critical for downstream success. As we know well, the immune response to immunization often focuses on a small number of antibody families with highly similar CDR3s which...
Get In Touch